Free Trial
NASDAQ:SNPX

Synaptogenix 11/12/2024 Earnings Report

Synaptogenix logo
$4.00 +0.42 (+11.73%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$3.98 -0.02 (-0.62%)
As of 04:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Synaptogenix EPS Results

Actual EPS
-$4.58
Consensus EPS
-$1.95
Beat/Miss
Missed by -$2.63
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synaptogenix Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Synaptogenix Earnings Headlines

The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
Synaptogenix Inc Ordinary Shares
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:SNPX) operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

View Synaptogenix Profile

More Earnings Resources from MarketBeat